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Introduction
The prevailing hypothesis for the metastatic spread of
cancer is that metastasis is the end stage of a progressive
disease [1]. Specifically, cancer cells acquire the hall-
marks of malignancy as they accumulate multiple, rate-
limiting mutations. Furthermore, this progression occurs
over an extended period of time, resulting in metastasis
being a rare event with long latency. Importantly, the
primary tenet behind early cancer detection and preven-
tion strategies is that carcinogenesis can be suppressed
during the post-initiation stages of the disease, specifically
because of its progressive nature and long latency [2].
Recently, however, the concept of cancer as a multistep
progression, with metastatic potential arising late within a
rare cell, has been challenged [3–5]. In this review we
discuss this controversy within the context of the tumor
microenvironment and address its implications for future
prevention and treatment research.
Requirement for multiple mutations
There is a tremendous body of literature that supports the
hypothesis that cancer results from the slow accumulation
of mutations that eventually give rise to rare variant cells
with metastatic potential. For example, for most epithelial
cancers there is evidence of a histologic progression of
the disease from benign through malignant stages. In
breast cancer this progression consists of atypical ductal
hyperplasia, preinvasive ductal carcinoma in situ (DCIS),
and invasive ductal carcinoma. For familial colorectal
cancer the histopathologic progression, as well as the
progression of genetic alterations, has been defined [6].
More recently, the histopathologic progression with corre-
sponding genetic mutation profiles have been described
for oral leukoplakia [7] and Barrett’s esophageal cancer
[8]. Experimental evidence supporting the hypothesis that
multiple genetic lesions drive the histopathologic progres-
sion of transformed epithelial cells is also very convincing.
In order for human epithelial cells to form colonies in soft
agar or tumors in immunocompromised mice, transforma-
tion with two or more known oncogenes is required [9].
More recently, Brugge and coworkers [10] demonstrated
that transfection with a combination of oncogenes – one
that causes constitutive proliferation cotransfected with
one that inhibits apoptosis – are required for lumen filling
in a three-dimensional culture model for breast cancer. A
single oncogene capable of activating both proliferation
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and antiapoptotic pathways, such as ErbB2, was also
found to mimic DCIS in culture. In further support of multi-
step carcinogenesis, these DCIS models did not exhibit
motile or invasive phenotypes, implicating the requirement
for additional mutational events [10].
Long latency consistent with multistep
carcinogenesis
Considerable data indicate that cancer progression from
premalignancy to malignancy is slow, which is consistent
with a natural selection model in which multiple mutations
are required in order to reach full metastatic potential. The
best clinical data demonstrating a long latency for tumori-
genesis comes from studying families with familial cancer
syndromes. Individuals from Li Fraumeni families who have
an inactive p53 gene due to a germ-line mutation are
essentially born with ‘initiated’ cells, and 90% of these
individuals develop cancer by age 70 years. However,
malignant transformation is limited to certain organs and
latency, which varies depending on organ site, is relatively
long in every case [11]. The average age of onset is
16 years for sarcomas, 37 years for breast cancer, and
50 years for lung cancer. Similarly, BRCA1 mutation carri-
ers have a 55–58% lifetime risk of developing breast
cancer (and much lower for ovarian cancer). Moreover, the
risk for breast cancer remains age related, beginning in
the 30s. This delay in latency may be due to two additional
events required: inactivation of the other BRCA1 allele
and a gain-of-function mutation that supports survival of
cells with no BRCA1. Something akin to this may also be
necessary for tumor development in Li Fraumeni patients.
Additional support for long latency being required for man-
ifestation of aggressive tumors is evident in cervical
cancer, where it is possible to identify readily early-stage
lesions. Progression of untreated cervical cancer from car-
cinoma in situ to invasive cancer has been reported to
take between 8 and 30 years [12,13].
Metastasis is a rare event, consistent with
end-stage disease
Finally, clinical evidence demonstrating that metastasis is
indeed a rare event in humans was definitively obtained by
Tarin and colleagues [14]. In their study, patients who had
metastatic spread of a variety of primary cancers to the
peritoneal cavity were fitted with peritoneovenous shunts.
With the shunt, abdominal pressure was alleviated by
delivering the ascites fluid, with viable cancer cells,
directly into the jugular vein. These metastatic tumor cells
would be anticipated to have a higher probability of suc-
cessfully colonizing distant organs than primary tumor
cells of similar metastatic potential. This is because initial
barriers to metastasis that primary tumor cells encounter
are circumvented, namely the need to disrupt cell–cell and
cell–matrix interactions within the primary tumor, invade
through the local tissue, and gain access to the local vas-
culature or lymphatics [15]. Further, in that study these
ascites fluid cells were already successful metastatic cells.
Based on blood samples taken from 16 patients, it was
estimated that on average 2 × 107 viable cells were
present per 20 ml blood, of which approximately 1 in 104
were clonogenic in soft agarose [14]. The average dura-
tion of exposure was 40 weeks. Most of the patients suc-
cumbed to complications of ascites fluid. At autopsy,
tissues were collected for semiquantitation of macro- and
micrometastases. Surprisingly, metastatic events were
rare, even in lung, which was the first capillary bed
encountered by the tumor cells (Table 1).
Data obtained from animal models, in which cells, either
transformed with known oncogenes or isolated from
metastatic tumors, were injected directly into the vascula-
ture, corroborate the human data. In these animal experi-
ments, formation of secondary lesions occurs only rarely,
with less than 0.001% of cells with metastatic potential
contributing to metastatic lesions [12,16,17]. One inter-
pretation of these data is that, even in a population of
seemingly identical metastatic cells, additional epigenetic
selection is required for cells to expand and successfully
form a tumor. Another interesting example of metastatic
inefficiency is demonstrated by the presence of
micrometastatic disease in bone marrow. Of patients with
primary esophageal and pancreatic carcinoma, 20% have
presumptive cancer cells in their marrow, even though
bone and bone marrow are rare sites of metastatic growth
[18,19]. In breast cancer, positive marrow has been asso-
ciated with a somewhat worse prognosis in stages I–III,
but not IV [20]. In total, the evidence is mixed and demon-
strates that marrow micrometastasis is clearly not a strong
prognostic factor.
Cumulatively, these clinical and experimental data support
the conclusions that cancer is a progressive disease with
metastasis being a rare event with a long latency. These
observations indicate that a cell must accumulate numer-
ous, independent mutations in order to overcome multiple,
rate-limiting barriers to metastasis.
Metastatic genotype acquired early: clinical
evidence
It is the recent expression profiling data obtained from
microarray analyses that have revitalized the question of
whether the metastatic phenotype represents end stage of
a lengthy progressive disease. Nagging doubts existed
before the advent of microarray technology. For example,
although a clear molecular progression profile correspond-
ing to histopathologic progression can be identified in
some cancers, in fact only a small percentage of these
cancers present with the ‘classic’ genetic mutation profile.
Furthermore, a relationship between progressive
increases in mutations and increasing histologic aggres-
siveness has not been identified for other common
cancers such as breast, lung, or prostate. These observa-95
tions indicate that mutations that result in a metastatic
phenotype are not necessarily late events, and rather that
it is the net cumulative effect of mutations that is more
important than the order in which they are acquired.
Further doubt that metastasis is, by definition, an attribute
acquired late in cancer progression has been obtained
from mammography screening. Surprisingly, population
scale screening has not decreased breast cancer mortality
rates as dramatically as was expected, suggesting that
early-stage breast cancers are not necessarily less
aggressive than later stage. In fact, between 22% and
33% of stage I breast cancers progress, indicating that
these early stage cancers have already spread at time of
detection [21].
These clinical observations are consistent with the idea
that within each stage there are more aggressive tumors
and less aggressive tumors. Furthermore, these data
suggest that, early on, cancers may be separable into
those with high metastatic potential and those without,
independent of stage at diagnosis. The recent microarray
data detailing the expression profiles of primary tumors
and corresponding metastatic lesions support this
concept [5,22–24].
Metastatic genotype acquired early:
molecular evidence
In the microarray studies the identification of gene expres-
sion profiles in stage I breast cancers was found to be
predictive of patient outcome [5,22–24]. Specifically, a
gene signature correlating with metastatic progression
could be found in a subpopulation of primary tumors.
Because microarray technology is not sensitive enough to
identify rare variant cells within the tumor mass, these
studies show that the propensity to metastasize is not a
rare event that occurs in only a few cells within the primary
tumor. Furthermore, microarray data have demonstrated
that expression profiles can be similar between early-stage
DCIS lesions and invasive breast tumors. Two additional
points can be made from these observations. First, tumors
can be segregated into those with and those without
metastatic potential at a clinical stage corresponding to
histologically premetastatic lesions [25]. Second, for
tumors with metastatic potential, there appear to be few
gene expression differences between preinvasive and
invasive lesions.
Although the potential implications of these data for identi-
fying at-risk patients are clear, the question of whether
metastasis is indeed the end stage of a progressive
disease, and whether metastasis-specific genes exist at
all, becomes less clear. In fact, Bernards and Weinberg
[3] recently argued that the same classes of genes
involved in cancer initiation (i.e. the classic oncogenes and
tumor suppressor genes that contribute to autocrine
growth factor production, resistance to cell death signals,
and genomic instability) may be the elusive metastasis
genes (or the upstream regulators of metastasis genes).
Support for this concept is evident in the aggressive phe-
notype observed in immortalized human mammary epithe-
lial MCF12A cells transfected with oncogenic V12-Ras
(Fig. 1). Introduction of the single oncogenic Ras gene
results in loss of the normal polarized mammary epithelial
phenotype and gain of an aggressive motile phenotype
consistent with a full epithelial-to-mesenchymal transition.
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Table 1
Post-intravasation models for metastatic efficiency
Peritoneal/venous shunts of ascitic fluid [14]
Average number of viable cells 
per 20 ml blood (delivered on  Average clonogenic efficiency  Metastatic events in patients at 
Site of primary tumor average for 40 weeks) in soft agar autopsy
Ovary, breast, pancreas  1 × 107 1 in 104 8/15: no viable cells
bronchus, and colon 7/15: large number of single 
viable tumor cells and 
micrometastases in lung only
Tail injection [16,17]
Cell types Gene expressed Number of cells per injection Lung colony efficiency
NIH-3T3 [16] c-H-ras 3 × 105 1 in 104
v-src 3 × 105 2 in 105
MDA-MB-231 [17] – 1.0 × 106 <1 in 105
MDA-MB-435 [17] – 1.0 × 106 <1 in 105
Data from references Tarin and coworkers [14], Egan and coworkers [16], and Price and coworkers [17].96
In total, clinical and experimental evidence are compelling
for both models of metastasis and suggest that some
tumors advance through classic progression stages and
acquire metastatic potential rather late, whereas other
tumors acquire this potential early on, possibly as early as
initiation.
Metastatic potential is not sufficient for
metastasis
When it became obvious that metastasis was a rare event,
even for fully transformed cells delivered directly into the
vasculature, it was hypothesized that most metastatic
tumor cells die in the vasculature because the environ-
ment is hostile [12,26]. More recently, using in vivo video
microscopy, Chambers and coworkers determined that
survival of tumor cells in the circulation, arrest of cells in
capillary beds within secondary organs, and extravasation
out of the capillary bed into the local tissue are in fact
highly efficient events [27]. Those researchers determined
that approximately 80% of the original tumor cell inocu-
lums arrested at a secondary site, and rather it was the
abilities of these arrested cells to develop into
micrometastases and then progress to vascularized
lesions that were highly inefficient. These live cell imaging
data, combined with the new gene profiling data, demon-
strate that having metastatic potential is not sufficient to
guarantee a successful metastatic event. So what deter-
mines whether a cell will manifest its malignant phenotype
and colonize a distant organ successfully?
Role of the microenvironment in determining
the metastatic phenotype
In fact, two steps in the metastatic cascade have been
described as rate limiting: gaining access to the vascula-
ture (or lymphatics) at the site of the primary tumor [28]
and tumor formation at the secondary site [29]. These
observations suggest that a permissive tumor micro-
environment is required for successful metastasis [27].
Specifically, the microenvironment of the primary tumor
needs to support tumor cell dissemination, motility, and
local invasion into the vasculature (intravasation), whereas
the microenvironment at the secondary site needs to
support cell adhesion, proliferation, and neovasculariza-
tion. The identification of these two rate-limiting steps to
metastasis is consistent with the ‘seed and soil’ hypothe-
sis originally put forth by Dr Stephen Paget in 1889 and
whose seminal work was recently reviewed [30]. Briefly,
Paget proposed that the metastatic cell (the seed)
requires an appropriate environment (the soil) for success-
ful growth at the secondary site [31]. One key role for the
microenvironment that has gained prominent recognition
is neovascularization. Tumors simply cannot progress
without concomitant growth and organization of the
stromal endothelial cells [32]. However, the role played by
the microenvironment in tumor development extends far
beyond the contribution of a blood supply [33]. Additional
mechanisms by which the microenvironment influences
metastatic behavior of tumor cells are varied and include
the following: changes in extracellular matrix (ECM) glyco-
protein composition, which can alter cell adhesion, motility,
proliferation, and apoptotic rates; altered ECM-degrading
proteinase activities within the stroma, which presumably
facilitate movement of tumorigenic cells by disrupting
stromal barriers; and release of bioactive ECM fragments
and/or growth factors that can promote or suppress neo-
plastic progression of both stromal and tumor cells.
Pathological changes to the
microenvironment and tumor progression
It has become increasingly evident that pathologic
changes in the tissue microenvironment can enhance
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Figure 1
Human mammary epithelial MCF12A cells stably transfected with
oncogenic V12Ras exhibit a functional epithelial-to-mesenchymal
transition, which is consistent with a metastatic phenotype. 
(a) Diagram of normal mammary epithelial cell with extensive cell–cell
junctional complexes, apical–basal polarity, and apical secretion. 
(b) Diagram of mesenchymal-like cell with lack of cell–cell junctions
and front to back polarity typical of a motile cell. (c) Immortalized but
non-tumorigenic MCF12A cells form a duct-like structure in three-
dimensional culture with polarized cells that have extensive cell–cell
interactions – attributes of normal mammary epithelial cells in vivo,
×400. (d) MCF12A cells transfected with oncogenic Ras show
characteristics of metastatic cells in three-dimensional culture, with
loss of cell–cell interactions and gain of front–back polarity, which are
hallmarks of the mesenchymal cell, ×400. BM, basement membrane;
GJ, gap junction; JC, junctional complex; ME, myoepithelial cell; MFG,
mammary fat globule.97
tumor cell progression [34–37]. In one study, newly
hatched chicks injected with Rous sarcoma virus only
developed tumors at the site of injection, even though
virus was found circulating in the blood. Furthermore, if a
wound was made away from the primary tumor, a tumor
developed at the site of wounding. Investigators verified
that secondary tumor development was dependent on
wound induced inflammation [38] – an observation con-
sistent with a significant body of clinical data demonstrat-
ing that pathology-induced inflammation appears to be an
etiologic factor in numerous epithelial cancers. The clinical
association between inflammation and cancer progression
is sufficiently strong to justify a myriad of ongoing anti-
inflammation based cancer chemoprevention and treat-
ment trials [39].
Importantly, tumor cells themselves can induce a reactive
stroma (i.e. desmoplasia), which can contribute to disease
progression. In prostate and breast cancers, normal
stromal fibroblasts are replaced by smooth muscle reac-
tive myofibroblasts, which hare also referred to as carci-
noma-associated fibroblasts (CAFs) [40–42]. These CAF
cells alter ECM composition, elevate cytokine production,
and induce infiltration of inflammatory cells. Evidence for
oncogenic function of these reactive stromal cells has
been obtained from studies in which immortalized but non-
tumorigenic epithelial cells were combined with CAFs and
engrafted into athymic nude mice. Using this strategy,
both prostate and keratinocyte tumorigenic conversion by
CAFs has been documented [43,44]. Similarly, irradiation
of an epithelial-stripped rodent mammary gland results in a
reactive stroma characterized by elevated transforming
growth factor-β. Subsequent injection of nontumorigenic
mammary epithelial cells into this stroma resulted in neo-
plastic progression [45]. These and other studies demon-
strate that local injury or tumor cells themselves, via
paracrine signaling to stromal cells, are capable of induc-
ing a pro-oncogenic microenvironment that is critical for
tumor cell progression. Remarkably, these experiments
demonstrate that the pathologic changes in tumor
microenvironment can be as important for disease pro-
gression as the mutational profile of the tumor cell itself.
That is, without a permissive environment, tumor progres-
sion may not occur.
Physiologic changes to the microenvironment
and tumor progression
More recently, physiologic changes in stroma have also
been implicated in tumor progression, opening up an
entirely new area for investigation. Normal human senes-
cent fibroblasts stimulate premalignant and malignant cells
to proliferate in culture and form tumors in mice [46].
Krtolica and Campisi [47] proposed that, as the number of
senescent fibroblasts increases with age, a pro-oncogenic
tissue environment is created that drives the rise in cancer
incidence that occurs with age.
In our laboratory we have focused on characterizing
changes in the mammary gland microenvironment induced
as a result of pregnancy. We have found that mammary
gland ECM isolated from glands regressing after preg-
nancy has attributes of reactive stroma, namely elevated
matrix metalloproteinase (MMP) activity and bioreactive
matrix fragments [48]. Furthermore, in comparison with
ECM obtained from quiescent glands, involution ECM sig-
nificantly enhanced tumor cell motility and invasion in vitro
[49]. Our data demonstrate that reproductive state alters
mammary ECM composition, which influences tumor cell
metastatic potential. These in vitro observations may shed
light on both pregnancy-associated breast cancer and the
‘dual effect’ pregnancy has on breast cancer risk. Specifi-
cally, we propose that the period of active tissue remodel-
ing that occurs during gland regression may create a
microenvironment that is permissive for tumor cell dissemi-
nation. Thus, women with occult disease at the time of
gland involution may be at increased risk for metastatic
spread, and older women would be at greatest risk
because they are more likely to have occult disease than
younger women.
The microenvironment and tumor suppression
The question of whether the tumor microenvironment can
actively inhibit metastasis is less well studied. However, the
fact that tumor cells can reside for decades in a dormant
state, combined with experiments that have determined
that tumor cells arrive at secondary sites at high rates but
fail to thrive in the new environment, effectively demon-
strate that the microenvironment can exert a significant pro-
tective effect. Importantly, experimental data demonstrate
that even fully malignant cells can undergo phenotypic
reversion, given the appropriate microenvironment.
In an elegant concept paper, Pierce and Speers [50] pro-
posed that this reversion occurs because of tissue interac-
tions similar to those that determine cell fate during
embryogenesis. The fact that the connective tissue of an
organ can dictate epithelial cell form and function is
common knowledge in the field of developmental biology,
where stromal–epithelial interactions have been studied
for well over a century [51]. Recently, the idea that the
microenvironment can be manipulated to induce tumor cell
reversion was experimentally verified. Disrupting tumor cell
interaction with the ECM via integrin blocking antibodies
resulted in phenotypic reversion in a breast cancer model
[52]. With antibody treatment, these aggressive, disorga-
nized malignant breast tumor cells reverted to well orga-
nized, polarized cells that formed ascini in culture. Of
potential in vivo relevance, it has been reported that mor-
phologically normal tissue, adjacent to breast carcinomas,
displays loss of heterozygosity similar to that displayed
within the tumor tissue [53]. One interpretation of these
observations is that progression of these adjacent cells to
an invasive phenotype is suppressed by their microenvi-
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ronment. The observation that stromal–tumor cell interac-
tions can actually inhibit disease progression brings us to
the following question; what is the role of the stromal
sheath that is often found encapsulating primary tumors?
Re-evaluating the tumor stroma
There is a fibrous tunic or sheath that encapsulates many
epithelial tumors (Fig. 2). The question of whether the
stromal sheath is a reaction by the host to contain the
tumor or whether it is the result of tumor–stromal inter-
actions that promote tumorigenesis has been considered
for decades. Although the majority of studies indicate a
promotional role for stroma in tumor progression, this may
be due to an inclination for disease-based research to
focus on causation. Furthermore, the focus has been on
the target cell (i.e. the epithelial cell) rather than on the cell
and its environment. For example, MMPs have long been
implicated in metastasis. This is because it is apparent
that in order to metastasize successfully, tumor cells must
invade local tissues. Thus, enzymes that are capable of
disrupting stromal barriers, such as the MMPs, are key
candidate mediators of invasion. Importantly, tumor
homogenates contain elevated MMP activity, and trans-
fection of tumor cells with MMP expression constructs
convincingly increases their tumorigenicity and metastatic
potential in both in vitro and in vivo models. Based on
these studies numerous inhibitors of MMPs were
designed, which were very effective at blocking tumori-
genesis of MMP over-expressing tumor cells in mouse
models. However, clinical trials evaluating the efficacy of
MMP inhibitors in human cancers were disappointing, and
in some cases MMP inhibition corresponded with tumor
progression.
A thought provoking synthesis of the MMP experimental
studies and clinical trials was recently reported by
Matrisian and colleagues [54]. In fact, in human cancers
most MMPs are synthesized by stromal cells rather than
by the tumor cells. Furthermore, some matrix proteolytic
fragments have been identified that appear to act as tumor
suppressors rather than tumor promoters. For example,
angiostatin (a 38-kDa internal proteolytic fragment of plas-
minogen) and endostatin (a 20-kDa carboxyl-terminal frag-
ment of collagen XVIII) are both endogenous inhibitors of
angiogenesis, and suppress tumor growth in animal
models [55,56]. Recently, the protease responsible for the
production of angiostatin in the Lewis lung carcinoma
model was identified as MMP-2 [57]. Thus, the ying–yang
of MMP activity in tumorigenesis becomes apparent. We
suggest that further study of the stromal sheath and the
desmoplastic response of tumors will identify a wealth of
additional stromal factors that will either promote or sup-
press epithelial tumor cells, depending on their stage of
transformation.
Targeting the stroma for cancer prevention
and treatment
An important question to be answered is whether the
microenvironment can be targeted for therapeutic or pre-
ventive strategies. Because the relationship between
epithelial cells and the microenvironment is complex, the
success of these strategies will undoubtedly be depen-
dent on stage of epithelial cell transformation. For
example, in a rodent model, hypoxia induced by angio-
genesis inhibition resulted in stimulation of tumor cell inva-
sion rather than inhibition, as anticipated [58]. This
unintended effect – promotion of metastasis – indicates
that the ‘genomic’ flux of the tumor cell must be taken into
account when developing antiangiogenic therapies [59].
However, data from two chemoprevention studies provide
proof of concept that the microenvironment can be
targeted to inhibit mammary tumor progression. We
demonstrated that chemopreventive doses of difluoro-
methylornithine and retinoids inhibit progression of chemi-
cally induced rat mammary tumors [60]. Treated animals
exhibited reduced mammary epithelial complexity, similar
to that observed in mammotrophic hormone depleted
mammary glands. Furthermore, changes in mammary
gland stroma, consistent with a desmoplastic reaction,
were apparent. Cumulatively, our data are consistent with
these chemopreventive agents causing a disruption of
epithelial cell–ECM interactions, resulting in epithelial cell
loss by apoptosis and subsequent protection of the
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Figure 2
Ductal carcinoma of the breast surrounded by a fibrous stromal sheath.
Depicted is a single duct containing an intraductal carcinoma. White
arrows show lumen-like structures; however, normal epithelial cell
polarity is lost. Black arrows show delineation between tumorigenic
mammary epithelial cells and stromal tissue. The asterisk shows
stromal sheath encapsulating the ductal carcinoma in situ.
Magnification: 400×. From University of Connecticut’s Virtual
Pathology Museum (http://pathweb.uchc.edu).99
mammary gland from tumor progression [48,60,61]. Simi-
larly, mammary glands of rats treated with protective
doses of conjugated linoleic acid exhibited a desmoplastic
stromal reaction, decreased epithelial cell proliferation,
and a decrease in angiogenesis [62]. Given the impor-
tance of stromal–epithelial interactions in determining
normal mammary gland development, tissue homeostasis,
and tumor progression, the observation that preventive
agents can target stroma is not surprising. The challenge
remains to gain a full understanding of these interactions
in order to maximize treatment efficacy for each stage of
transformation.
Conclusion
In summary, epithelial cell transformation is necessary but
not sufficient for metastasis. The microenvironment is as
rate-limiting with respect to metastatic success as is the
genotype of the tumor cell itself. Stromal cells contribute
to both tumor cell suppression and progression, with
current data suggesting that the ratio of stromal inhibitors
to promoters determines tumor cell fate. Finally, even fully
malignant cells appear to be able to undergo phenotypic
reversion in the appropriate environment. A model depict-
ing the permissive and suppressive functions that the
microenvironment can impart on tumor cell phenotype is
summarized in Fig. 3. Given the critical role of the environ-
ment to metastatic success, it is likely that control of
metastasis will only be accomplished by investing in
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